Stroke

Austin, TX

29 Stroke Trials near Austin, TX

Power is an online platform that helps thousands of Stroke patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Brain State-Dependent PCMS for Stroke Recovery

Austin, Texas
After stroke, people often have difficulty using their hands. Combined brain and nerve stimulation can strengthen the neural pathways that control hand function. In this study, we will deliver combined brain and nerve stimulation during specific time windows that increase activation of neural pathways underlying hand function. We will compare the effects of combined brain and nerve stimulation during these optimal time windows to the effects of combined brain and nerve stimulation applied during random time windows on post-stroke hand function.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2

45 Participants Needed

TMS for Stroke Recovery

Austin, Texas
Transcranial magnetic stimulation (TMS) interventions could feasibly strengthen residual corticospinal tract (CST) connections and promote poststroke hand motor recovery. To maximize the effects of such interventions, they must be delivered during brain activity patterns during which TMS best activates the residual CST and enhances its neural transmission. This approach is termed brain state-dependent TMS. The investigators have recently developed a machine learning framework that identifies personalized brain activity patterns reflecting strong CST activation in neurotypical adults. In this study, the investigators will apply this framework to the poststroke brain for the first time. They will also evaluate relationships between this framework's ability to detect strong and weak CST activation states and measures of CST pathway integrity. Participants will visit the laboratory for two days of testing that are separated by at least one night of sleep. On Day 1, participants will provide their informed consent. The MacArthur Competence Assessment Tool and the Frenchay Aphasia Screening Test will be used to evaluate consent capacity and confirm the presence of expressive aphasia as needed. Afterwards, participants will complete eligibility screening and clinical assessment of upper extremity motor impairment, motor function, and disability using the Upper Extremity Fugl-Meyer Assessment, the Wolf Motor Function Test, and the Modified Rankin Scale. Participants will then be screened for the presence of residual CST connections from the lesioned hemisphere to the affected first dorsal interosseous muscle. Recording electrodes will be attached to this muscle in order to record TMS-evoked twitches in these muscles. During this procedure, single-pulse TMS will be applied to each point of a 1 cm resolution grid covering primary and secondary motor areas of the lesioned hemisphere at maximum stimulator output. If TMS reliably elicits a muscle twitch in the affected first dorsal interosseous, that participant will be considered to have residual CST connections and will be eligible for the full study. If no muscle twitch is observed, the participant will not be eligible for the full study. Afterwards, recording electrodes will be removed and the participant will leave the laboratory. On Day 2, participants will return to the laboratory. The investigators will confirm continued eligibility and place recording electrodes on the scalp using a swim-type cap. The investigators will also place recording electrodes on the affected first dorsal interosseous as well as the affected abductor pollicis brevis and extensor digitorum communis muscles. After identifying the scalp location at which TMS best elicits muscle twitches in the affected first dorsal interosseous muscle, the investigators will determine the lowest possible TMS intensity that such evokes muscle twitches at least half of the time. Then, the investigators will deliver 6 blocks of 100 single TMS pulses while participants rest quietly with their eyes open. Stimulation will be delivered at an intensity that is 20% greater than the lowest possible TMS intensity that evokes muscle twitches at least half the time. Afterwards, all electrodes will be removed, participation will be complete, and participants will leave the laboratory. The investigators will recruit a total of 20 chronic stroke survivors for this study.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

20 Participants Needed

Personalized TMS for Stroke

Austin, Texas
Transcranial magnetic stimulation (TMS) interventions could feasibly strengthen residual corticospinal tract (CST) connections and enhance recovery of paretic hand function after stroke. This project will test whether personalized brain state-dependent TMS can activate the residual corticospinal tract better than standard TMS, and evaluate the relationship between this activation and hand motor impairment.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

37 Participants Needed

Left Atrial Appendage Exclusion for Stroke Prevention

Austin, Texas
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

6573 Participants Needed

Nerve Stimulation + Knee Brace for Post-Stroke Mobility Improvement

Austin, Texas
The purpose of this study is to examine the reflex excitability of the rectus femoris in individuals with and without post-stroke Stiff-Knee gait. We use electrical stimulation of the peripheral nerve innervating the rectus femoris for a well-controlled reflex stimulus. We are investigating whether reflex excitability of the rectus femoris correlates with gait kinematics.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

60 Participants Needed

WATCHMAN FLX Device for Atrial Fibrillation

Austin, Texas
The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

3000 Participants Needed

AMPLATZER PFO Occluder for Patent Foramen Ovale

Austin, Texas
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 60

1214 Participants Needed

CLAAS Device for Atrial Fibrillation

Austin, Texas
This trial is testing a new heart device called the CLAAS® to see if it works as well as other similar devices. It is aimed at patients with a specific type of irregular heartbeat that can lead to strokes. The device helps by blocking off a small part of the heart to stop blood clots from forming.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

1600 Participants Needed

Milvexian for Stroke

Austin, Texas
This trial is testing whether milvexian can help prevent another stroke in people who have already had one by stopping blood clots from forming. Milvexian may reduce the risk of stroke without significant bleeding.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:40+

15000 Participants Needed

Cholesterol-Lowering Medication for Heart Attack

Austin, Texas
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction \[NSTEMI\] and ST-segment elevation myocardial infarction \[STEMI\]).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4

6019 Participants Needed

Amulet™ 2 Occluder for Atrial Fibrillation

Austin, Texas
The primary objective of this study is to evaluate the safety and effectiveness of Abbott's Amulet™ 2 Left Atrial Appendage (LAA) occluder device (Amulet 2 device) in patients who have non-valvular atrial fibrillation and who are at increased risk for stroke and systemic embolism and have appropriate rationale to seek a non-pharmacologic alternative to oral anticoagulation.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

458 Participants Needed

WATCHMAN FLX Pro Device for Atrial Fibrillation

Austin, Texas
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

1857 Participants Needed

Left Atrial Appendage Occlusion vs. NOAC for Atrial Fibrillation

Austin, Texas
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

2650 Participants Needed

Left Atrial Appendage Closure Devices for Atrial Fibrillation

Austin, Texas
The purpose of this study is to compare the safety and effectiveness of Laminar Left Atrial Appendage Closure (LAAC) device as compared to the commercially available LAAC devices in participants with non-valvular atrial fibrillation (NVAF) to reduce the risk of stroke (blocked blood vessel or bleeding in brain) and systemic embolism (blockage in a blood vessel harming vital organs).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

1900 Participants Needed

WATCHMAN Device for Atrial Fibrillation

Austin, Texas
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

4000 Participants Needed

BCI-Controlled Devices for Motor Disorders

Austin, Texas
Injuries affecting the central nervous system may disrupt the cortical pathways to muscles causing loss of motor control. Nevertheless, the brain still exhibits sensorimotor rhythms (SMRs) during movement intents or motor imagery (MI), which is the mental rehearsal of the kinesthetics of a movement without actually performing it. Brain-computer interfaces (BCIs) can decode SMRs to control assistive devices and promote functional recovery. Despite rapid advancements in non-invasive BCI systems based on EEG, two persistent challenges remain: First, the instability of SMR patterns due to the non-stationarity of neural signals, which may significantly degrade BCI performance over days and hamper the effectiveness of BCI-based rehabilitation. Second, differentiating MI patterns corresponding to fine hand movements of the same limb is still difficult due to the low spatial resolution of EEG. To address the first challenge, subjects usually learn to elicit reliable SMR and improve BCI control through longitudinal training, so a fundamental question is how to accelerate subject training building upon the SMR neurophysiology. In this study, the investigators hypothesize that conditioning the brain with transcutaneous electrical spinal stimulation, which reportedly induces cortical inhibition, would constrain the neural dynamics and promote focal and strong SMR modulations in subsequent MI-based BCI training sessions - leading to accelerated BCI training. To address the second challenge, the investigators hypothesize that neuromuscular electrical stimulation (NMES) applied contingent to the voluntary activation of the primary motor cortex through MI can help differentiate patterns of activity associated with different hand movements of the same limb by consistently recruiting the separate neural pathways associated with each of the movements within a closed-loop BCI setup. The investigators study the neuroplastic changes associated with training with the two stimulation modalities.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

100 Participants Needed

Smartwatch-Guided DOAC Therapy for Atrial Fibrillation

Austin, Texas
This trial tests whether taking blood-thinning medication continuously or only when a smart watch detects an irregular heartbeat is better for adults with a history of irregular heartbeats and moderate stroke risk.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:22 - 85

5350 Participants Needed

Edoxaban for Atrial Fibrillation

Austin, Texas
This trial is testing if edoxaban, a daily blood-thinning medication, can safely reduce stroke risk in high-risk atrial fibrillation patients who have had previous brain bleeds. The goal is to see if it works better than not using any blood thinners or using simpler treatments. Edoxaban has been shown to be effective in preventing stroke with a lower risk of bleeding.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:45+

948 Participants Needed

Retatrutide for Obesity

Austin, Texas
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:45+

10000 Participants Needed

Inclisiran for Cardiovascular Disease Prevention

Pflugerville, Texas
This trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40 - 79

14082 Participants Needed

Why Other Patients Applied

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

Asundexian for Stroke Prevention

Temple, Texas
This trial is testing asundexian, a new medicine that prevents blood clots, in people who had a non-heart-related stroke or high-risk mini-stroke. The goal is to see if it works better at reducing future strokes without increasing bleeding risks. Asundexian is developed by Bayer AG and might prevent thrombosis without increasing bleeding.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

12327 Participants Needed

PFO Closure Device for Preventing Stroke

Temple, Texas
This study will assess the safety and effectiveness of GORE® CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a post-market setting.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

636 Participants Needed

MW189 for Brain Bleed

San Antonio, Texas
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

120 Participants Needed

Redasemtide for Stroke

San Antonio, Texas
This trial is testing a medication called redasemtide to see if it can help adults who have had a stroke. The goal is to find out if this medication can protect brain cells and help them heal better after the stroke. Researchers are looking at both how well it works and if it is safe to use.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

849 Participants Needed

Endovascular Thrombectomy for Stroke

San Antonio, Texas
STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

1600 Participants Needed

Anti-Coagulant + Anti-Platelet Therapy for Stroke Prevention

San Antonio, Texas
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:30+

1683 Participants Needed

Apixaban vs Aspirin for Stroke Prevention in Atrial Fibrillation After Brain Bleed

San Antonio, Texas
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

700 Participants Needed

Oral Ketones for Heart Failure

San Antonio, Texas
This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF). Plasma ketones are avidly extracted by cardiac muscle and their uptake is not dependent upon insulin or influenced by insulin resistance.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1

10 Participants Needed

Evolocumab for Heart Disease

San Antonio, Texas
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50 - 79

12301 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Stroke clinical trials in Austin, TX pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Stroke clinical trials in Austin, TX work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Stroke trials in Austin, TX 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Austin, TX for Stroke is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Austin, TX several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Stroke medical study in Austin, TX?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Stroke clinical trials in Austin, TX?

Most recently, we added Brain State-Dependent PCMS for Stroke Recovery, Endovascular Thrombectomy for Stroke and Amulet™ 2 Occluder for Atrial Fibrillation to the Power online platform.

Is it possible to 100% recover from a stroke?

A completely symptom-free recovery does happen, but it’s uncommon—about 1 in 10 stroke survivors have no noticeable deficits by 3–6 months, while many more regain independence yet live with minor limitations. Your odds rise if the stroke is small, treated within hours (clot-busting drugs or thrombectomy), and followed by early, high-intensity rehab; age, other illnesses, and strong family support also matter. Even when full recovery isn’t reached, the brain can keep rewiring for months or years, so aggressive therapy and strict control of blood pressure, cholesterol, and lifestyle risks remain worthwhile.

What triggers a stroke?

A stroke is triggered the instant blood can’t reach part of the brain—either because a clot suddenly blocks an artery or a weakened vessel bursts. Long-standing problems such as high blood pressure, atrial fibrillation, diabetes, smoking, and cholesterol build-up make the vessels fragile, while short-term sparks like a surge in blood pressure (heavy exertion, intense stress, cocaine or binge drinking), a bad infection, severe dehydration, or head/neck injury can tip things over the edge. Controlling the chronic risks and avoiding those sudden spikes are the surest ways to lower your odds.

What is the new procedure for stroke victims?

Two main “new” procedures are worth knowing about. If a stroke is caught within the first day, doctors can now thread a tiny device into the brain’s artery (mechanical thrombectomy) to pull out large clots—even up to 24 hours after symptoms start. For people who are six months or more past an ischemic stroke and still have arm weakness, a recently approved treatment called paired vagus-nerve stimulation implants a pacemaker-like device in the chest; brief pulses are delivered during therapy sessions and, in a large study, nearly doubled the number of patients who regained meaningful arm use compared with therapy alone. Ask your stroke or rehab specialist which option, if any, fits your stage of recovery and medical history.

What is the average age at the time of ischemic stroke?

Across contemporary U.S. and European studies, the average (mean) age at first ischemic stroke is about 70–72 years overall—roughly 71 years in men and 74–75 years in women. Most strokes still occur after 65, but nearly 15–20 % now happen before age 55, so personal risk depends more on controllable factors such as blood-pressure, diabetes, smoking, and atrial fibrillation than on age alone.

What are good signs after a brain stroke?

Good signs after a stroke are the things doctors see when the brain is healing: 1) steadily improving neurological function—e.g., a weak arm or leg starts to move, speech becomes clearer, swallowing is safe, thinking is sharper; 2) growing independence—being able to sit, stand, walk, dress, or bathe with less help each week; and 3) no new problems—vital signs remain stable, follow-up scans show no bleeding or new damage, and there are no new bouts of confusion or weakness. If progress keeps inching forward over the first days to months, that generally predicts a better long-term recovery, while sudden setbacks should prompt a call to the medical team.

Which side of the brain is worse to have a stroke?

Neither hemisphere is automatically “worse.” What harms you most is how big the stroke is, which critical areas it hits (for example, language centers on the left or spatial-awareness areas on the right), and how fast doctors can restore blood flow. Large right-side strokes carry a slightly higher risk of early swelling and heart-rhythm problems, while left-side strokes more often steal speech, but in the long run size, exact location, and treatment speed—not simple left vs. right—determine survival and disability.

How to stop a stroke in progress?

A stroke in progress can only be halted by hospital teams, so the single lifesaving move is to get the patient to a stroke-ready ER fast. Spot symptoms with the BE-FAST check (Balance, Eyes, Face, Arm, Speech, Time), call 911, note when symptoms started, keep the person upright and nil-by-mouth, and let EMS transport. Every minute saved lets doctors give clot-busting medicine (within ~4½ h) or remove a clot mechanically (up to 24 h in select cases), drastically reducing brain damage and disability.

What is the critical time after a stroke?

“Time is brain.” Call 911 the moment you notice stroke signs, because the sooner doctors see you, the more treatment choices you have: clot-busting medication helps most if started within 4½ hours, and a catheter procedure to pull out a large clot can work in carefully selected cases up to 24 hours—but outcomes get worse with every minute’s delay. Getting to the hospital fast also lets the team quickly scan your brain, control bleeding or swelling, and begin early rehab, all of which greatly improve the chance of recovery.

What heals the brain after a stroke?

First, rapid hospital treatment (clot-busting drugs or a catheter procedure, plus careful control of blood pressure, sugar and swelling) “saves” threatened brain tissue—so minutes matter. In the weeks and months that follow, the surviving brain rewires itself and grows new blood vessels, and that self-repair works best when you give it the right signals: daily, task-specific rehab exercises, regular aerobic activity, good sleep, and strict control of smoking, blood pressure, cholesterol and diabetes; tools like non-invasive brain stimulation or certain medications are optional add-ons guided by specialists. Put simply, the brain heals through a mix of early damage-limiting care and long-term, repetitive practice in a healthy body, with emerging technologies offering extra (but still experimental) help for some people.

What is the average stay in rehab after a stroke?

For patients able to tolerate intensive therapy, the average stay in a U.S. inpatient rehabilitation hospital is about 15–18 days (roughly 2–3 weeks); if a skilled-nursing rehab unit is needed, expect closer to 4–5 weeks before stepping down to outpatient or home therapy several times a week. How long you personally stay hinges on stroke severity, other medical problems, progress on daily-living skills, insurance rules, and the safety of your home setup—so ask the rehab team what specific goals you must meet to move to the next level of care.

Popular Searches

By Condition

Depression Clinical Trials in Texas

Anxiety Clinical Trials in Texas

Schizophrenia Clinical Trials in Texas

ADHD Clinical Trials in Texas

Bipolar Disorder Clinical Trials in Texas

Multiple Sclerosis Clinical Trials in Texas

Autism Clinical Trials in Texas

Treatment Resistant Depression Clinical Trials in Texas

Borderline Personality Disorder Clinical Trials in Texas

Social Anxiety Disorder Clinical Trials in Texas

Parkinson's Disease Clinical Trials in Texas

Alzheimer's Disease Clinical Trials in Texas

By Location

Clinical Trials near Houston, TX

Clinical Trials near Dallas, TX

Clinical Trials near San Antonio, TX

Clinical Trials near Austin, TX

Clinical Trials near Fort Worth, TX

Clinical Trials near Plano, TX

Clinical Trials near Tyler, TX

Clinical Trials near El Paso, TX

Clinical Trials near Lubbock, TX

Clinical Trials near Galveston, TX

Clinical Trials near Temple, TX

Clinical Trials near Arlington, TX

Other People Viewed

By Subject

Top Clinical Trials near East China Township, MI

Top Clinical Trials near Abingdon, VA

Top Bowel Cancer Clinical Trials

Top Clinical Trials near Gardena, CA

177 Clinical Trials near Draper, UT

188 Clinical Trials near Jerseyville, IL

116 Diabetes Type 1 Trials Near You

Top Clinical Trials near Cincinnati, OH

Top Clinical Trials near Maryland

Top Diabetes Clinical Trials near Fort Lauderdale, FL

Top Leiomyosarcoma Clinical Trials near Glendale, AZ

Top Clinical Trials near Fishers, IN

By Trial

Low-Nicotine Cigarettes for Heart Health

DBT Skills Group for Suicide Risk

E-Cigarettes for Nicotine Addiction

Glucose and Ketone Monitoring for Type 1 Diabetes

Peposertib + Tuvusertib for Advanced Cancer

Long-Term Safety of AAA617 for Prostate Cancer

Atogepant vs Topiramate for Migraine

Testicular Tissue Freezing for Infertility

Mental Health Program for People Living With HIV

Nab-Sirolimus + Endocrine Therapy for Ovarian Cancer

Digital Symptom Tracking for Advanced Cancer

Cognitive Behavioral Therapy for Menopause

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial